Lipigon Pharmaceuticals Second Quarter 2024 Earnings: kr0.003 loss per share (vs kr0.10 profit in 2Q 2023)
Lipigon Pharmaceuticals (STO:LPGO) Second Quarter 2024 Results
Key Financial Results
- Revenue: kr9.12m (down 43% from 2Q 2023).
- Net loss: kr415.0k (down by 106% from kr7.13m profit in 2Q 2023).
- kr0.003 loss per share (down from kr0.10 profit in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Lipigon Pharmaceuticals Earnings Insights
Looking ahead, revenue is forecast to grow 90% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden.
Performance of the Swedish Biotechs industry.
The company's shares are down 9.1% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 7 warning signs for Lipigon Pharmaceuticals (of which 5 make us uncomfortable!) you should know about.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:LPGO
Lipigon Pharmaceuticals
Develops drugs for lipid related diseases in Sweden.
High growth potential with excellent balance sheet.